BioPharm-Medicine.com
  • Home
    • About Us
    • Stories >
      • Bernadette's Story
      • Sharyn's Story
  • Roles
    • Executive Positions
    • Pharmacology/Toxicology
    • Clinical Research
    • Biostatistics
    • Data Management
    • Regulatory Affairs
    • Medical Writing
    • Medical Affairs
    • Clin. Res. Organizations (CROs)
    • Consultants & Contractors
  • Teamwork
    • Investigator's Brochure
    • Clinical Study Reports
    • Filing an NDA
    • Promotional Review Committee
  • Training
    • Common Abbreviations
    • Canadian HPFB
    • Clinical Reseach >
      • Clinical Study Reports
      • Draft PI
      • Investigator's Brochure
      • Phases of Clinical Development
    • Discovery/Design >
      • Toxicology
      • PharmacologyPK
    • The FDA >
      • The IND
      • The NDA
      • The PI
    • European Regulations
    • Safety/Pharmacovigilance
  • Resources
    • CME
    • European Agencies
    • FDA websites & Org Charts
    • Guidance Docs and Guidelines
    • Professional Organizations
    • Other Links
  • Protocol Writing

Medical Affairs
BioPharm companies that have products on the market, or coming to market, usually have a Department of Medical Affairs.  Medical Affairs staff enhance communications with physicians, pharmacists and consumers and help separate the exchange of medical information from commercial activities.  Physicians, PharmDs, and PhDs fill many important roles in Medical Affairs. 

Medical Affairs Departments may include one or more of the following services;

 Medical Information, sometimes called Medical Communications, a group that  provides information about the company’s products to consumers and prescribers;
 
 Medical Writing, a group that prepared educational materials or helps with
     publications;

 
 Medical Science Liaisons (MSLs), a group of physicians, pharmacists or other
    scientists who interact with key physicians or Investigators;

  
 Safety, also know as Pharmacovigilance,  a group responsible for reporting postmarketing adverse drug reactions;
  
 Clinical Research, a team of medical monitors, CRAs, data managers and
     Biostatisticians who conduct Phase IV or line extension studies and
   
 Patient Support, a team focused on consumer education and/or access to and
    financial
assistance for the company’s products.

Some companies are too small to have separate departments for each of these activities and they may depend upon their Clinical Research staff for assistance.  Some companies outsource some of the activities to outside consultants or contract organizations. One way or another, the important work of Medical Affairs gets done.  

Let's look a bit more at some of these activities.


Medical Information
Physicians and PharmDs play important roles in Medical Information.  They may be Department heads or individual contributors.  The Department of Medical Information usually has a team of pharmacists, or nurses, or other staff who answer questions about the use of the companies drugs from physicians, patients and families, or the media.  Also responses must be honest and balanced; they must provide both positive and negative information.  Safety is key in all interactions. 

Why do companies need Departments of Medical Information?

 BioPharm companies can only “promote” their products for the indication(s) approved by the FDA.  This means that the company can only publicize the information from their product Prescribing Information  when writing journal ads, on websites, or meetings with physicians.  This Prescribing Information, also called the  "PI" or "the Label", is the detailed information form supplied with each prescription drug.  The PI is developed with the FDA at the time that the drug is approved and it can be updated  with postmarketing information.  The PI included detailed information about the chemistry, indications, dosing, safety and efficacy of the drug.   A copy of the PI is shipped with each package of the drug and it is listed in resources such as the Physician's Desk Reference.  Companies must also put links to full PI prescribing information on any drug websites.   But physicians often want to know more about the drug or device than that found in the PI.  


Any information about the drug that is not contained in the PI is considered "off label".  Sales reps and marketing staff cannot answer questions about unapproved "off-label" use but Medical Information Departments can.  Current regulations allow companies to answer "unsolicited" questions any about unapproved use as long as the responses are truthful, balanced, non-promotional, and responsive to the specific request.  The term “unsolicited”, means that the company cannot encourage the physician to ask the questions.  In most companies, staff from Medical Information or MSLs are responsible for answering these questions.

For example, let’s assume your company markets an immunosuppressant drug  that is approved for prevention or treatment of kidney rejection.  A doctor asks a sales rep if the product could be used for liver transplants.  A sales representative would have to say, "Doctor, I don't have any information about that but I will have someone from our Medical staff contact you.  A Medical Information staff person could contact the doctor, by phone, by e-mail, or in person.  The staff person would first remind the doctor that the product was not “approved” for hepatic rejection, only for kidney rejection and offer to provide the approved PI.  But then, s/he could discuss any safety or efficacy results the company had that related to use of the drug in patients who had undergone liver transplantation.  This could be information from clinical studies  conducted by the company or other information in the medical literature.  If there were both positive and negative studies, s/he would have to give all of the information, both the good and the bad.  
But the Med Affairs representative could not discuss studies  about use after heart transplant unless the doctor asked specifically about heart transplants or unless there was some important safety information to convey. The Medical Affairs department would need to record of this interaction to show that a balanced response had been given, that approved Prescribing Information had been offered, and to show that the company was not soliciting physicians to ask about liver transplants;  only responding to legitimate requests.  

We have provided a link to the FDA Draft Guidance called 
Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices in the Guidance page in Resources. If you are interested in Medical Affairs, I would encourage you to read this Guidance.

Medical Safety Liaisons (MSLs)
There is a growing opportunity for doctors in the role of Medical Safety Liaisons (MSLs), sometimes call Scientific Advisors.  MSLs are usually physicians, PharmDs, or PhDs, with specialized training in therapeutic fields of interest to the company.  MSLs are usually part of Medical Affairs Departments.  MSLs often call upon academic physicians, the so called “Key Opinion Leaders” (KOLs), and physicians or pharmacy groups. They provide in-depth scientific information at medical meetings.  They serve as peers to the prescribing community and scientific experts within the company.  

Clinical Research
Medical Affairs departments may also have their own Clinical Research groups including medical monitors, CRAs, biostatisticians, and data management staff.   Physicians, PharmDs, and PhDs all play roles as team leaders or medical monitors. These doctors develop protocols, help plan data collection and study analysis, recruit researchers and supervise the conduct of the study, usually with a team of CRAs.  They may also be responsible for reporting the results and presenting abstracts at meetings.  Physicians in Clinical Research may also assist academic investigators with investigator-sponsored studies. These Clinical Research groups follow the same GCP regulations as other Clinical Development groups but they can help prioritize Phase 4 or line extension studies of interest to the commercial group.  

Postmarketing Safety and Pharmacovigilance
Physicians also play important roles in Safety Departments, again as Department Heads or monitors. In clinical trials, adverse events are actively solicited; at every study visit patients are asked whether or not they have had any adverse events.  The investigator assesses whether or not the event is related to the study drug or device and determines whether the event is Serious.  After a product is marketed things are a bit different.  If a physician, pharmacist, patient or a family member calls to report a problem with a drug or device the assumption is that they must think the adverse event is drug or device-related.  Each of these events must be reported as Adverse Drug Reactions (ADRs).  In addition, a lack of effect, i.e. “a failure of the drug to produce the expected pharmacologic action”, is also considered to be an adverse experience with a marketed drug and must be reported.  So, if a patient calls to ask for a refund because his/her pain medication did not help, that is an adverse experience and must be reported. For more details about postmarketing safety reporting, we have included links to two FDA Guidance Document the Guidance tab in the Resource section.  

An example of the role of a physician in Medical Affairs
My first role in industry was in Medical Affairs, in a Department called Medical Services.  Our Medical Services group included Medical Information, Medical Writing, and Safety Reporting.  Our company had about 20 marketed products and 5-6 more drugs in development;  I was assigned responsibility for several of these drugs. 

I worked with the pharmacists in the Medical Information group to respond to "queries" about our products from prescribers, pharmacists, and patients.  Back then, our questions came by mail, phone, or from the Sales representatives.  Today, queries also come via e-mail and social-media.   All of our responses included a PI for the approved indication for the drug and references from the literature or in-house materials (“information on file”) to support our responses.

I worked with the Medical Information group to prepare balanced, clinically meaninful responses to physician's questions.   I also worked with medical writing teams to prepare educational materials about the products such as drug monographs and supplemental educational materials  like slide sets,  focused on the targeted diseases. 

We had a Safety group that handled reports of postmarketing adverse drug reactions. I reviewed the information, contacted the reporting physicians  to get additional details
if necessary, and worked with the Regulatory Affairs  to submit reports to the FDA.   

I loved the job.  It had it’s own share of headaches, some major, some trivial, but it was exciting and the job forced me to relearn basic information from my medical training that I had almost forgotten.  What is the formula to estimate renal clearance?  And to review key anatomy,  physiology, gynecology, virology, analgesia, etc.  

One of my other responsibilities was to be part of the Promotional Review Committee approve the medical information in any ad for my drugs.  Other people reviewed the legal and regulatory components of the ad.  One of my assigned products was an NSAID analgesic used for sports injuries.  I remember being asked to approve an illustration of a sprained ankle that would be used for a drug ad in an  important orthopedic journal.  The medical illustrator had drawn a swollen ankle, with an “incision” that depicted an internal view of the torn ligaments.  I had cared for many patients with sprained ankles, but never pictured the pathology so graphically. Nevertheless, it was my job to make sure that the anatomy was correct.  I went to Gray’s Anatomy and Grant’s Atlas to refresh my memory of the bones, ligaments and tendons of the foot. The anatomy books showed AP and lateral views of the ankle, but the medical illustrator had gone one step further.  She had chosen a unique view, from overhead, just as the foot would look if the ligaments and tendons had been exposed at surgery-- a view that did not match my reference books.  So, I spent several hours trying to decide if the drawing was OK.  I did not want to be flooded with complaints from orthopedic surgeons telling us that we had gotten it wrong!  I finally approved the ad and sent it to the printers.  Fortunately, the medical illustrator had done a great job and we had no complaints.

The Future of Medical Affairs
The responsibilities of Medical Affairs will probably expand and evolve and a job in Medical Affairs will continue to be an exciting role for BioPharm doctors.  It takes a unique skill set to fill these jobs.  In 2012, the consulting group, McKinsey & Company,

summarized their vision of Medical Affairs for 2020 and beyond (see link in Resources).  In this article, the McKinsey authors described the skills needed by doctors who work in Medical Affairs.

   “The bar is high for Medical Affairs talent. They need to collaborate with R&D
   colleagues and deeply understand the science that underpins their work; they
   must understand the rules and regulations governing the industry almost as well
   as their compliance and legal department colleagues; and they should have the
   strategic thinking capabilities of their marketing counterparts as well as the  
    customer-interaction skills of their colleagues in sales.”
 


Further Information
There are two organizations dedicated to helping people with careers in Medical Affairs and/or as Medical Science Liaisons. 
If you go to our Resource page, you will find a link to the Medical Science Liaison Society, a non-profit organization dedicated to advancing what they call “the global MSL career”.  The MSLS website provides some the history and a concise description of the role of MSLs today, a link to educational resources and career links. 

​There is a also a link to the Accreditation Council for Medical Affairs (ACMA).  The ACMA offers courses leading to Board Certification in Medical Affairs and shorter Certificate courses focused on topics such as Medical Affairs, the Medical Device Industry, Understanding Diagnostics, Clinical Development, Pharmacoeconomics, Fundamentals of Industry Compliance, and Regulatory Affairs.   Many of these certificate programs are eligible for CME or CE credit.